Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with ...
Aldosterone escape and non-ACE pathways for angiotensin II production may explain, at least in part, the continued high mortality rates in heart failure patients despite the advances made in ...
A highly selective aldosterone synthase inhibitor, lorundrostat, showed promise for blood pressure reduction in a double-blind randomized phase IIb trial. Participants with uncontrolled and otherwise ...
Resistant and severe hypertension represent a growing global health burden and are associated with a markedly increased risk of cardiovascular, renal, and ...
With almost half of American adults living with high blood pressure, it makes sense that you'd want every possible tool in ...
Successfully met the primary endpoint in the BrigHtn trial, delivering a 20.3 mmHg reduction in systolic blood pressure (SBP), or an 11 mmHg (p-value 0.0001) decline on a placebo-adjusted basis, at 2 ...
Please provide your email address to receive an email when new articles are posted on . A seated saline suppression test had a high false-negative rate for predicting response to primary aldosteronism ...
An investigational antihypertensive agent that inhibits the enzyme involved in aldosterone production, called MLS-101, significantly reduces blood pressure in patients with uncontrolled and resistant ...
A drug that has been used to slow progression of kidney and cardiovascular disease in people with type 2 diabetes may also help people with chronic kidney disease who do not have diabetes, according ...
The symptoms of hyperkalemia begin with muscle weakness. As serum potassium levels rise, symptoms progress to more significant muscle twitching, weakness, nausea, and cramping. [69] Cardiac conduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results